MedTrace Logo

Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST

NCT02638766 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2023-03-27

No results posted yet for this study

Summary

Evaluate the treatment with regorafenib in patients with metastatic and/or unresectable KIT/PDGFR wild type GIST in the first line setting.

Conditions

Interventions

DRUG

regorafenib

Treatment with regorafenib 160mg once a day, 3 weeks on / 1 week off in cycles of 28 days

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Grupo Espanol de Investigacion en Sarcomas

    lead OTHER

Principal Investigators

  • Javier Martín-Broto, MD · GEIS (GRUPO ESPAÑOL DE INVESTIGACION EN SARCOMAS

  • Virginia Martínez-Marín, MD · GEIS (GRUPO ESPAÑOL DE INVESTIGACION EN SARCOMAS

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-11-30
Primary Completion
2021-08-31
Completion
2021-08-31

Countries

  • France
  • Italy
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02638766 on ClinicalTrials.gov